Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition, and changes in the metabolic profile of obese patients following 3-week body mass reduction program: a randomized clinical trial

Table 3 Baseline clinical characteristic of RO, AO, and C groups

Variable	RO group (n = 26)	AO group (n = 26)	C (n = 29)	P-value
Age	50.7 ± 13.5	46.6 ± 10.4	49.9 ± 13.4	0.273^a
Fasting plasma glucose, mg/dL	105.0 (98.0–119.0)	110.5 (95.0–131.0)	104.0 (98.0–114.0)	0.852^b
Fasting insulin, μU/L	18.5 (11.3–29.3)	22.6 (13.2–27.5)	15.5 (13.0–22.2)	0.591^b
HOMA-IR	4.8 (2.9–7.5)	6.1 (3.2–8.9)	4.0 (3.3–5.3)	0.410^b
TC, mg/dL	196.6 ± 39.5	193.8 ± 37.0	192.5 ± 47.8	0.944^a
HDL, mg/dL	48.0 (41.0–66.0)	42.5 (37.0–48.0)	49.0 (42.0–57.0)	0.060^b
HDL, %	29.2 (19.0–33)	21.1 (18.0–29.6)	26.0 (22.0–32.0)	0.191^b
non-HDL, mg/dL	143.5 ± 39.8	149.6 ± 39.7	149.1 ± 43.9	0.773^a
TG/HDL ratio	2.3 (1.4–4.0)	3.7 (2.4–5.4)	2.9 (2.0–5.6)	0.090^b
LDL, mg/dL	121.5 ± 33.9	117.6 ± 35.1	108.0 ± 36.6	0.484^a
TG, mg/dL	97.0 (79.0–177.0)	143.0 (103.0–204.0)	142.0 (104.0–196.0)	0.082^b

Normally distributed data are represented by mean ± SD and skewed data by the median (interquartile range). P < 0.05 is considered significant
^aone way ANOVA, ^bKruskal-Wallis test,
Abbreviations: HDL high-density lipoprotein cholesterol, HOMA-IR homeostatic model assessment of insulin resistance, LDL low-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides, SI conversion factors: to convert TC, HDL, and LDL to mmol/L, multiply by 0.02586; TG to mmol/L, by 0.0114; glucose to mmol/L, by 0.05551

ISSN: 1476-511X